Professor Moein Moghimi, PhD
(email at email@example.com)
Moein Moghimi joined Durham University in 2016 where he serves as Professor and Chair of Pharmaceutics at the School of Medicine, Pharmacy and Health. He is also a Full Affiliate Member/Professor at the Department of Translational Imaging, Houston Methodist Research Institute, Houston Methodist Hospital Systems (Houston, Texas, USA) and Adjoint Professor at the Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Denver Medical Center (USA). In 2015, Moein was a Visiting Professor at Università Degli Studi Di Padova, Italy. Between 2008 and March 2016, he was based at the University of Copenhagen (Denmark) serving as Professor of Nanomedicine at the Department of Pharmacy, Professor of Pharmaceutical Nanotechology at the NanoScience Centre, and the Founder and Director of the multi-million Euro Centre for Pharmaceutical Nanotechnology and Nanotoxiocology (the first interdisciplinary nanomedicine research centre in Denmark). Between 2008 and 2010, he further served as the Honorary Professor of Nanomedicine at the Multidisciplinary Research Center, Shantou University (China). His earlier appointments included a Senior Lectureship position in Biopharmacy and Molecular Pharmaceutics at the School of Pharmacy, University of Brighton and The University Research Fellow in Advanced Drug Delivery Systems at the Department of Pharmaceutical Sciences, University of Nottingham.
Over the past two decades, Professor Moghimi has been practicing in the capacity of advisor/consultant to over 50 pharmaceutical, biotechnology, health and food industries as well as investment banks, management consultancy firms and other entrepreneurial enterprises worldwide. He is a regular invited assessor and expert evaluator in nanomedicine/nanosafety programmes for governmental bodies, research councils and private organizations (over 50 establishments in 25 countries).
Professor Moghimi’s research activities are focused on pharmaceutical nanoscience, nanomedicine and nanosafety. More specifically, Professor Moghimi has made a major contribution to design and surface engineering of nanoparticles and functional nanosystems for parenteral site-specific targeting/drug delivery and imaging modalities (splenotropic entities, lymphotropic agents, ‘phagocyte-resistant’ nanoparticles, cerebral endothelial cell specific nanoplatforms and anti-cancer nanomedicine) as well as mechanistic understanding of nanomaterial/polymer-mediated infusion reactions and cell death processes. Professor Moghimi’s interdisciplinary research has been recognized by many international awards and to date he has been able to secure over €10 million in competitive research funds as principal investigator. Furthermore, he has partnered large-scale competitive European Commission FP-7 programmes in translational nanomedicine/drug delivery, addressing Alzheimer’s disease (The NAD Project) and atherosclerosis (CosmoPHOS NANO). In 2014 the NAD project was published as success story by Horizon 2020, endorsed by the EU President and received the prestigious Best Project Award in the category of completed projects under the European Union Framework programme in the field of industrial technologies. As of 2016, Professor Moghimi has edited multiple journal issues and is an author on >200 peer-reviewed journal articles and >10 patent/disclosure applications. He has given >300 invited seminars and keynotes in more than 30 countries.
A nanometer is 1000 million (one billion) times smaller than the world of meters. At nanoscale, materials and substances behave differently and show altered chemical and physical properties compared with their larger-particle kin. This incredibly low scale allows for unique interactions among atoms and their constituent parts and opening the path for the materials of the future including biomaterials and nanotherapeutics. The latter encompasses technologies and system approaches that achieve and facilitate earlier and more precise individual diagnosis, improved targeted therapies (eliminating side effects) and enhanced therapeutic monitoring. On a broader context, these approaches are enabling tools for personalized and targeted medicine that can deal with the grand challenges of chronic diseases in an aging population. Images above are examples of such technologies under development in this laboratory. The left-portion corresponds to cutting-edge multifaceted and “tailor-made” polymeric, lipid- and peptide-based nanoconstructs and drug delivery platforms capable of incorporating small molecules, diagnostic agents and biopharmaceuticals. These enabling technologies are directed for better management and more effective treatment of cancer, neurological pathologies (e.g., Alzheimer’s disease), cardiovascular diseases (e.g., atherosclerosis), arthritis, and allergy. The right-portion depict examples of targeted nanosystems in various human cell types, where intracellular trafficking and the fate of delivery systems is followed by real-time fluorescent microscopy and transmission electron microscopy.
Following completion of secondary education at d’Overbroeck’s College Oxford (UK), Moein studied biochemistry at the University of Manchester (UK) and in 1989 earned his PhD in biochemistry from Charing Cross and Westminster Medical School (Imperial College). He then completed a four-year SERC-funded post-doctoral training programme in Advanced Drug Delivery Research at the School of Pharmaceutical Sciences (University of Nottingham, UK).
- Nanoparticle engineering for medicine
- Systems approaches to site-specific targeting and controlled drug delivery and release
- Nucleic acid therapeutics
- Mechanistic aspects of injection-related adverse reactions to nanopharmaceuticals & nanomedicine
- "Structure-activity" cascade and real-time medium-throughput integrated approaches for determination of nanopharmaceutical performance at cell and molecular levels
- Mechanistic aspects of integrated efficacy-safety profiling of nanopharmaceuticals
- Experimental T-cell therapies
Indicators of Esteem
- Editorial Functions:
- Editorial Board Member - Advanced Drug Delivery Reviews
- Editorial Board Member - AIMS Genetics
- Editor-in-Chief - Current Bionanotechnology
- Editorial Board Member - Current Drug Discovery Technologies
- Section Editor (Immunology) - Current Pharmaceutical Biotechnology
- Editorial Board Member - Drug Delivery
- Associate Editor - Journal of Biomedical Nanotechnology
- Editorial Board Member - Journal of Controlled Release
- Editorial Board Member - Journal of Drug Delivery
- Editorial Board Member - Journal of Liposome Research
- Editorial Board Member - Nanomedicine-UK
- Associate Editor (2010-2015) - Nanomedicine: Nanotechnology, Biology and Medicine
- Editorial Board Member - Molecular and Cellular Therapies
- Editorial Board Member – Recent Patents on Drug Delivery and Formulation
- Journal Issues Edited/Co-Edited:
- Maturitas (2012) 73, Issue 1.
- Nanomedicine: Nanotechnol. Biol. Med. (2012) 8, Supplement 1.
- Adv. Drug Deliv. Rev (2011) 63, Issue 12.
- Nanomedicine: Nanotechnol. Biol. Med. (2011) 7, Issue 5, Nanomedicine and Alzheimer’s Disease.
- J. Biomed. Nanotechnol. (2009) 5, Issue 6.
- Adv. Drug Deliv. Rev (2006) 58, Issue 14.
- Curr. Drug Deliv. (2005) 2, Issue 4.
- Adv. Drug Deliv. Rev (2000) 41, Issue 2.
- Adv. Drug Deliv. Rev (1995) 17, Issue 1.
- Research Featured as Journal Cover Stories:
- 2016 Journal of Controlled Release. Front Cover and Cover Story 221(10 Jan): http://www.sciencedirect.com/science/article/pii/S0168365915007956
- 2015 European Journal of Nanomedicine. Front Cover 7(3): http://www.degruyter.com/view/j/ejnm.2015.7.issue-3/issue-files/ejnm.2015.7.issue-3.xml
- 2013 Bioimpacts. Front Cover 3(1): http://bi.tbzmed.ac.ir/JournalIssues/AllIssues/Volume3Issue1.aspx
- 2012 Nanomedicine: Nanotechnology, Biology and Medicine. Front Cover 8(2A): http://www.sciencedirect.com/science/article/pii/S1549963412004121
- 2011 Nature Nanotechnology. News & Views 6(04 Feb): http://www.nature.com/nnano/journal/v6/n2/full/nnano.2011.4.html
- 2011 Advanced Drug Delivery Reviews. Front Cover 63(12): http://www.sciencedirect.com/science/journal/0169409X/63/12
- Selected Recent Invited Lectures/Speeches, Chairs, Keynotes (K) and Plenaries (P):
- 2016 NanoBioMed; Krems-Austria (K)
- 2016 CLINAM, Basel-Switzerland
- 2016 Engineering Conferences International, Schloss Herrnstein; Herrnstein-Austria
- 2016 Mechanism and Brriers in Nanomedicine, Breckenridge-CO-USA
- 2016 Food Allergy Summit, London-UK
- 2016 8th International Nanotxicology Congress, Boston-MA-USA
- 2016 European Federation for Pharmaceutical Sciences Annual Meeting, Antalya-Turkey
- 2016 18th International Pharmaceutical Technology Symposium, Antalya-Turkey
- 2016 2nd International Conference on Immune Responses to Biosurfaces, Rhodes-Greece
- 2015 ESF/EMBO, Pultusk-Poland (K)
- 2015 Canton Nucleic Acid Forum, Guangzhou-China
- 2015 Department of Surgery, University of Hong Kong, HK
- 2015 18th Annual Meeting of ASGCT, New Orleans-LA-USA
- 2015 11th International Symposium on Pharmaceutical Sciences, Ankara-Turkey (P)
- 2015 CLINAM, Basel-Switzerland
- 2015 CRS Malaysia Local Chapter, Kuala Lumpur-Malysia (P)
- 2015 12th Annual World Congress of SBMT on Brain/Spinal Cord Injury, Los Angeles-CA-USA
- 2015 Pharma and Food Lecture Series, University of Vienna, Vienna-Austria
- 2014 Cedars Sinai Medical Center, Los Angeles-CA-USA
- 2014 Walk and Talk at Nanoscale, Venice-Italy (K)
- 2014 17th International Pharmaceutical Technology Symposium, Antalya-Turkey
- 2014 Liposome Research Days, Copenhagen-Denmark
- 2014 University of Denver, Denver-CO-USA
- 2014 17th World Congress of Basic and Clinical Pharmacology, Cape Town-South Africa
- 2014 11th International Conference on Nanosciences and Nanotechnology, Thessaloniki-Greece
- 2014 NanoTOES, Siena-Italy (P)
- 2014 Semmelweis University, Budapest-Hungary
- 2014 Nanotechnologies in Cancer Treatment, Torino-Castello del Valentino, Turin-Italy
- 2014 BioNanoMed, Krems-Austria (K)
- 2014 Methodist Research Institute, Houston-TX-USA
- 2013 Sanofi Research and Development, Paris-France (P)
- 2013 Nanoscience and Health, Center for Nanoscience in Ile de France, Paris-France (P)
- 2013 Institut Galien Paris-Sud, UMR CNRS, Chatenay-Malabry-France
- 2013 International Multidisciplinary Symposium on Drug Research and Development, Antalya-Turkey (P)
- 2013 Cell Mol Ther, Shanghai-China (P)
- 2013 CRS Italian Chapter, Pavia-Italy (P)
- 2013 The Annual Meeting of German Pharmaceutical Society, Frieburg-Germany 2013 (P)
- 2013 Nanotechnology Characterization Laboratory, Frederick-MD-USA
- 2013 Nanotechnologies in Cancer Diagnosis, Therapy and Prevention, NY Acad Sci, New York- NY-USA
- 2013 Nanoparticles and Nanotechnology in Medicine, Zambon Pharma Group – Bresso, Milan-Italy (P)
- 2013 University of California-Santa Barbara, Santa Barbara-CA-USA
- 2013 Stanford University, CA-USA
- 2013 Daniels College of Business, University of Denver, Denver-CO-USA
- 2013 Bridges in Life Sciences 8th Annual Scientific Conference, Prague-Czech Republic (P)
- 2013 Smart and Green Interfaces, COST ACTION, Czech Republic (P)
- 2012 Downscaling Science, Volkswagen Foundation’s 1st Herrenhausen Conference, Hanover-Germany
- 2012 Danish Cardiovascular Research Academy Annual Meeting, Sandbjerg, Denmark (K)
- 2012 Nanoteknlogi Fremtidens Laboratorie, Nohr-Con, Copenhagen-Denmark (P)
- 2012 3rd National Nano and Micromechanics Conference, Warsaw-Poland (P)
- 2012 8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Istanbul-Turkey
- 2012 Joint NanoImpactNet-QNano conference, Dublin-Ireland (K)
- 2012 CLINAM, Basel-Switzerland
Chapter in book
- Farhangrazi, Z.S. & Moghimi, S.M. (2016). Nanomedicine: Shadow and Substance. In Handbook of Clinical Nanomedicine: Law, Business, Regulation, Safety and Risk. Bawa, Raj, Audette, Gerald F. & Reese, Brian Boca Raton: Pan Stanford. 1081-1090.
- Wibroe, PP, Halvig, SY & Moghimi, SM (2015). The Role of Complement in Antibody Therapy for Infectious Diseases. In Antibodies for Infectious Diseases. 63-74.
- Parhamifar, L, Andersen, H, Wu, L, Hall, A, Hudzech, D & Moghimi, SM (2014). Polycation-Mediated Integrated Cell Death Processes. In Nonviral Vectors for Gene Therapy - Lipid- and Polymer-based Gene Transfer. 88: 353-398.
- Wang, Guankui, Griffin, James I., Inturi, Swetha, Brenneman, Barbara, Banda, Nirmal K., Holers, V. Michael, Moghimi, Seyed Moein & Simberg, Dmitri (2017). In Vitro and In Vivo Differences in Murine Third Complement Component (C3) Opsonization and Macrophage/Leukocyte Responses to Antibody-Functionalized Iron Oxide Nanoworms. Frontiers in Immunology 8: 151.
- Wibroe, P.P., Ahmadvand, D., Oghabianc, M.A., Yaghmur, A. & Moghimi, S.M. (2016). An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome. Journal of Controlled Release 221: 1-8.
- Moghimi, S.M., Hunter, A.C. & Peer, D. (2016). Platelet mimicry: The emperor's new clothes?. Nanomedicine: Nanotechnology, Biology and Medicine 12(1): 245-248.
- Wibroe, P.P., Petersen, S.V., Bovet, N., Laursen, B.W. & Moghimi, S.M. (2016). Soluble and immobilized graphene oxide activates complement system differently dependent on surface oxidation state. Biomaterials 78: 20-26.
- Moghimi, S.M., Wibroe, P.P., Wu, L. & Farhangrazi, Z.S. (2015). Insidious pathogen-mimicking properties of nanoparticles in triggering the lectin pathway of the complement system. European Journal of Nanomedicine 7(3): 263-268.
- Inturi, S., Wang, G., Chen, F., Banda, N.K., Holers, V.M., Wu, L., Moghimi, S.M. & Simbery, D. (2015). Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake. ACS Nano 9(11): 10758-10768.
- Hall, A., Parhamifar, L., Lange, M.K., Meyle, K.D., Sanderhoff, M., Andersen, H., Roursgaard, M., Larsen, A.K., Jensen, P.B., Christensen, C., Bartek, J. & Moghimi, S.M. (2015). Polyethylenimine architecture-dependent metabolic imprints and perturbation of cellular redox homeostasis. Biochimica et Biophysica Acta (BBA) - Bioenergetics 1847(3): 328-342.
- Jamnani, FR, Rahbarizadeh, F, Shokrgozar, MA, Mahboudi, F, Ahmadvand D, Sharifzadeh, Z, Parhamifar, L & Moghimi, SM (2014). T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: Towards tumor-directed oligoclonal T cell therapy. Biochimica et Biophysica Acta (BBA) - General Subjects 1840(1): 378-386.
- Andersen, AJ, Robinson, JT, Dai, H, Hunter, AC, Andresen, TL & Moghimi, SM (2013). Single-Walled Carbon Nanotube Surface Control of Complement Recognition and Activation. ACS Nano 7(2): 1108-1119.
- Moghimi, SM, Hunter, AC & Andresen, TL (2012). Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective. Annual Review of Pharmacology and Toxicology 52(1): 481-503.
- Moghimi, SM, Wibroe, PP, Helvig, SY, Farhangrazi, ZS & Hunter, AC (2012). Genomic perspectives in inter-individual adverse responses following nanomedicine administration: The way forward. Advanced Drug Delivery Reviews 64(13): 1385-1393.
- Brambilla, D, Verpillot, R, Le Droumaguet, B, Nicolas, J, Taverna, M, Kona J, Lettiero, B, Hashemi, SH, De Kimpe, L, Canovi, M, Gobbi, M, Nicolas, V, Scheper, W, Moghimi, SM, Tvaroška, I, Couvreur, P & Andrieuz, K (2012). PEGylated Nanoparticles Bind to and Alter Amyloid-Beta Peptide Conformation: Toward Engineering of Functional Nanomedicines for Alzheimer’s Disease. ACS Nano 6(7): 5897-5908.
- Moghimi, SM, Peer, D & Langer, R (2011). Reshaping the Future of Nanopharmaceuticals: Ad Iudicium. ACS Nano 5(11): 8454-8458.
- Moghimi, SM & Hunter, AC (2010). Complement monitoring of carbon nanotubes. Nature Nanotechnology 5(6): 382-383.
- Hamad, I, Al-Hanbali, O, Hunter, AC, Rutt, KJ, Andresen, TL & Moghimi, SM (2010). Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways at the Nanosphere−Serum Interface: Implications for Stealth Nanoparticle Engineering. ACS Nano 4(11): 6629-6638.
- Hamad, I, Hunter, AC, Szebeni, J & Moghimi, SM (2008). Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Molecular Immunology 46(2): 225-232.
- Mukhopadhyay, R, Al-Hanbali, O, Pillai, S, Hemmersam, AG, Meyer, RL, Hunter, AC, Rutt, KJ, Besenbacher, F, Moghimi, SM & Kingshott, P (2007). Ordering of Binary Polymeric Nanoparticles on Hydrophobic Surfaces Assembled from Low Volume Fraction Dispersions. Journal of the American Chemical Society 129(44): 13390-13391.
- Moghimi, SM, Hamad, I, Andresen, TL, Jørgensen, K & Szebeni, J (2006). Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. The FASEB Journal 20(14): 2591-2593.
- Moghimi, SM, Symonds, P, Murray, JC, Hunter, AC, Debska, G & Szewczyk, A (2005). A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Molecular Therapy 11(6): 990-995.
- Moghimi, SM, Hunter, AC & Murray, JC (2005). Nanomedicine: current status and future prospects. The FASEB Journal 19(3): 311-330.
- Moghimi, SM, Hunter, AC, Murray, JC & Szewczyk, A (2004). Cellular Distribution of Nonionic Micelles. Science 303(5658): 626-627.
- Moghimi, SM & Szebeni, J (2003). Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Progress in Lipid Research 42(6): 463-478.
- Moghimi, SM, Hunter, AC & Murray, JC (2001). Long-Circulating and Target-Specific Nanoparticles: Theory to Practice. Pharmacological Reviews 53(2): 283-318.